Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.
View/ Open
Date
2019-02Author
Sonnenblick, A
Bailey, A
Uziely, B
Untch, M
Smith, I
Gianni, L
Baselga, J
Jackisch, C
Cameron, D
Bell, R
Zardavas, D
Al-Sakaff, N
Gelber, RD
Dowsett, M
Leyland-Jones, B
Piccart-Gebhart, MJ
DE Azambuja, E
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based therapy. PATIENTS AND METHODS:HERA is an international randomized trial of 5,102 women with HER2-positive EBC, who were enrolled to either receive adjuvant trastuzumab or not. In this exploratory analysis, the interaction between autoimmune history and the magnitude of trastuzumab benefit was evaluated. RESULTS:A total of 5,099 patients were included in the current analysis. Among them, 325 patients (6.4%) had autoimmune disease history, 295 of whom had active disease. Patients were randomly assigned to trastuzumab or no-trastuzumab groups. Similar reductions in the risk of events in patients with and without autoimmune history were observed (interaction p=0.95 for disease-free survival, and p=0.62 for overall survival). CONCLUSION:No evidence of a differential benefit from trastuzumab in patients with a medical history of autoimmune disease was found.
Subject
Humans
Breast Neoplasms
Autoimmune Diseases
Disease-Free Survival
Treatment Outcome
Chemotherapy, Adjuvant
Proportional Hazards Models
Risk
International Cooperation
Adult
Aged
Middle Aged
Female
Trastuzumab
Antineoplastic Agents, Immunological
Research team
Medicine (RMH Smith Cunningham)
Endocrinology
Language
eng
Date accepted
2019-01-10
License start date
2019-02
Citation
Anticancer research, 2019, 39 (2), pp. 797 - 802